News
NRXP
1.160
-7.20%
-0.090
NRx Pharmaceuticals reports Q3 results
Seeking Alpha · 5h ago
Press Release: NRx Pharmaceuticals (NASDAQ:NRXP) -2-
Dow Jones · 7h ago
NRx Pharmaceuticals files to sell 3.3M shares of common stock for holders
TipRanks · 10h ago
NRx Pharmaceuticals Reschedules Conference Call To Discuss Q3 And Year To Date 2024 Financial Results To November 18, 2024
Benzinga · 1d ago
NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) RESCHEDULES CONFERENCE CALL TO DISCUSS THIRD QUARTER AND YEAR TO DATE 2024 FINANCIAL RESULTS TO NOVEMBER 18, 2024
Reuters · 1d ago
Weekly Report: what happened at NRXP last week (1104-1108)?
Weekly Report · 3d ago
NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) TO REPORT THIRD QUARTER AND YEAR TO DATE 2024 FINANCIAL RESULTS ON NOVEMBER 14, 2024
Reuters · 11/07 21:06
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024
Barchart · 11/07 15:06
Weekly Report: what happened at NRXP last week (1028-1101)?
Weekly Report · 11/04 10:22
HOPE Therapeutics and NRx Pharmaceuticals to buy Florida Interventional Psychiatry Clinics
Seeking Alpha · 10/30 14:41
NRX Pharmaceuticals Price Target Maintained With a $31.00/Share by EF Hutton
Dow Jones · 10/30 13:01
NRX Pharmaceuticals Is Maintained at Buy by EF Hutton
Dow Jones · 10/30 13:01
EF Hutton Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target
Benzinga · 10/30 12:51
NRx signs non-binding LOI to acquire Interventional Psychiatry Clinics
TipRanks · 10/30 11:50
HOPE THERAPEUTICS- ACQUISITION EXPECTED TO BE IMMEDIATELY ACCRETIVE TO REVENUE AND EBITDA
Reuters · 10/30 11:47
Weekly Report: what happened at NRXP last week (1021-1025)?
Weekly Report · 10/28 10:17
EF Hutton Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation
NASDAQ · 10/22 02:37
NRx started at buy by EF Hutton, cites suicide prevention focus
Seeking Alpha · 10/21 18:44
NRX Pharmaceuticals Price Target Announced at $31.00/Share by EF Hutton
Dow Jones · 10/21 11:40
EF Hutton Initiates Coverage On NRX Pharmaceuticals with Buy Rating, Announces Price Target of $31
Benzinga · 10/21 11:31
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.